ArticleAntimicrobial agents and chemotherapy2009
Development of NS3/4A protease-based reporter assay suitable for efficiently assessing hepatitis C virus infection.
Article in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 23 citations in OpenAlex.
- Precision bacterial immunotherapy: an integrated mechanistic taxonomy and translational roadmap against antimicrobial resistance.Frontiers in immunology · 2025Review
- Cell Cultures for Virology: Usability, Advantages, and Prospects.International journal of molecular sciences · 2020Review
- Rapid Determination of Ebolavirus Infectivity in Clinical Samples Using a Novel Reporter Cell Line.The Journal of infectious diseases · 2017Article
- Live Cell Reporter Systems for Positive-Sense Single Strand RNA Viruses.Applied biochemistry and biotechnology · 2016Review
- A Dual-reporter system for real-time monitoring and high-throughput CRISPR/Cas9 library screening of the hepatitis C virus.Scientific reports · 2015Article
- Visualizing hepatitis C virus infection in humanized mice.Journal of immunological methods · 2014Review
- Green tea phenolic epicatechins inhibit hepatitis C virus replication via cycloxygenase-2 and attenuate virus-induced inflammation.PloS one · 2013Article
- A Gaussia luciferase cell-based system to assess the infection of cell culture- and serum-derived hepatitis C virus.PloS one · 2012Article
- Hepatitis C virus experimental model systems and antiviral drug research.Virologica Sinica · 2010Review
- A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A cell culture system for the production of hepatitis C virus (HCV) whole virions has greatly accelerated studies of the virus life cycle and the discovery of anti-HCV agents. However, the quantification of the HCV titers in a whole-virus infection/replication system currently relies mostly on reverse transcription-PCR or immunofluorescence assay, which would be cumbersome for high-throughput drug screening. To overcome this problem, this study has generated a novel cell line, Huh7.5-EG(Delta4B5A)SEAP, that carries a dual reporter, EG(Delta4B5A)SEAP. The EG(Delta4B5A)SEAP reporter is a viral protease-cleavable fusion protein in which the enhanced green fluorescence protein is linked to secreted alkaline phosphatase (SEAP) in frame via Delta4B5A, a short peptide cleavage substrate for NS3/4A viral protease. This study demonstrates that virus replication/infection in the Huh7.5-EG(Delta4B5A)SEAP cells can be quantitatively indicated by measuring the SEAP activity in cell culture medium. The levels of SEAP released from HCV-infected Huh7.5-EG(Delta4B5A)SEAP cells correlated closely with the amounts of HCV in the inocula. The Huh7.5-EG(Delta4B5A)SEAP cells were also shown to be a suitable host for the discovery of anti-HCV inhibitors by using known compounds that target multiple stages of the HCV life cycle. The Z'-factor of this assay ranged from 0.64 to 0.74 in 96-well plates, indicating that this reporter system is suitable for high-throughput screening of prospective anti-HCV agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.